THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc.® (NasdaqCM:RPRX) today announced it has completed two animal model studies of the use of Proellex® in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company. Most importantly, extrapolating the data from the exposure seen in animals to that seen in humans, administration of Proellex via the vaginal route may achieve maximum circulating concentrations that are approximately 2% of that exhibited in humans at the 50 mg dose and only 6.5% of the lowest oral dose, 12.5 mg, previously tested in humans.
